- Global Pharma News & Resources

Insights on the Peptide Therapeutics Global Market to 2030 - Key Industry Trends and Forecasts -

DUBLIN--(BUSINESS WIRE)--The "Peptide Therapeutics Market by Type of Peptide, Route of Administration, Key Geographical Regions and Key Therapeutic Area: Industry Trends and Global Forecasts, 2021 - 2030" report has been added to's offering.

This report features an extensive study of the current market landscape of peptide therapeutics. The study also includes an elaborate discussion on the future potential of this evolving market.

Over the years, the rising popularity of biologics, such as peptide therapeutics, have led to an evident shift in the focus of the healthcare industry, from traditional small molecule-based interventions to upcoming, albeit complex, family of pharmacological interventions. The success of peptide therapeutics, so far, can be attributed to their clinical benefits, which include high target specificity, low toxicity and favorable safety profiles. Since 2017, over 10 peptide-based drugs have received marketing approvals across different regions of the world. Examples of recently approved peptide drugs include (in the reverse chronological order of approval) LupkynisT (2021), Mycappsa (2020), Scenesse (2019), Rybelsus (2019) and Vyleesi (2019). Further, more than 150 therapeutic peptides are currently under clinical investigation, while several novel leads are being evaluated in the early stages of research. In this context, it is also worth mentioning that peptide-based therapy products account for 5% of the global pharmaceutical revenues generated annually.

Presently, several drug developers, along with technology providers, are actively engaged in the development of novel peptide therapeutics, such as peptide drug conjugates and cell penetrating peptides. Innovation in this field of research is mostly focused on improving drug delivery methods, API stability, target affinity, and optimizing toxicity profiles. Several big pharma players have also demonstrated interest in peptide therapeutics and are investing both time and capital in this domain. Since 2019, more than USD 3 billion has been invested into companies that are involved in the development of various types of peptide drugs. In addition, the market is witnessing significant partnership activity; several licensing agreements, focused on drug development and commercialization, were recently inked between stakeholders in this industry.

Companies Mentioned

  • 13therapeutics
  • 7 Med Health Ventures
  • 9 Meters Biopharma
  • Abbott
  • Abingworth
  • Acorn Bioventures
  • ACT Capital Management
  • Adage Capital Management
  • Adams Street Partners
  • Advanced Accelerator Applications
  • Aileron Therapeutics
  • AJU IB Investment
  • Akashi Therapeutics
  • Alexion Pharmaceuticals
  • Allergan
  • Allysta Pharmaceuticals
  • Alphabet venture arm
  • Altimmune
  • Amgen
  • Amolyt Pharma
  • Ampio Pharmaceuticals
  • Amyndas Pharmaceuticals
  • Andera Partners
  • Angiochem
  • Anji Pharmaceuticals
  • AOP Orphan Pharmaceuticals
  • Apellis Pharmaceuticals
  • Apeptico
  • APIM Therapeutics
  • Apitope
  • Aquestive Therapeutics
  • Arch Biopartners
  • ARCH Venture Partners
  • Arix Bioscience
  • Asahi Kasei
  • AsclepiX Therapeutics
  • Astellas Pharma
  • AstraZeneca
  • Atlas Venture
  • Atox Bio
  • Aurinia Pharmaceuticals
  • Avilex Pharma
  • Avion Pharmaceuticals
  • Barer & Son Capital
  • Bayer
  • Becker
  • Belfius
  • Bergens forskningsstiftelse
  • Beth Israel Deaconess Medical Center
  • Better Ventures
  • Bicycle Therapeutics
  • Biogenosis
  • Bioglan
  • BioLineRx
  • Biolingus
  • BioMarin Pharmaceutical
  • Biomedical Advanced Research and Development Authority (BARDA)
  • BiomedInvest
  • BioMedPartners
  • Biomarck Pharmaceuticals
  • Bios Partners
  • Biosciences Research & Commercialization Center
  • BioSkin
  • BL&H
  • Boehringer Ingelheim
  • Boehringer Ingelheim Venture Fund
  • Boryung Pharmaceutical
  • Bossa Ventures
  • Boston Therapeutics
  • Bpifrance
  • Brightlands Life Sciences Ventures
  • Bristol Myers Squibb
  • Buttonwood
  • BVF Partners
  • Cambridge Innovation Capital (CIC)
  • Canaccord Genuity
  • Canadian Glycomics Network
  • CanBas
  • Cancer Research UK
  • Capital Community Angels
  • And Many More Companies!

One of the key objectives of the report was to estimate the existing market size and future opportunity associated with peptide therapeutics, over the next decade. Based on the sales for approved peptide drugs, during the period 2015-2020, we have developed informed estimates on the evolution of the market over the coming decade. Additionally, the report features the likely distribution of the current and forecasted opportunity across [A] type of peptide (small, medium and large), [B] route of administration (intravenous, oral, subcutaneous, topical and others), [C] key geographical regions (North America, Europe, Asia-Pacific and Rest of the World) and [D] key therapeutic area (metabolic diseases, oncological diseases, endocrine diseases, digestive and gastrointestinal diseases and others). In addition, the report provides value creation analysis of approved and clinical peptide-based therapies across different therapeutic areas.

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

Key Questions Answered

  • Who are the leading industry players engaged in the development of peptide therapeutics?
  • Which key disease indications are targeted by peptide therapeutic candidates in the current development pipeline?
  • What are the different initiatives undertaken by big pharma players for the development of peptide therapeutics in the recent past?
  • What kind of partnership models are most commonly adopted by stakeholders engaged in this domain?
  • Who are the key stakeholders that have actively made investments in the peptide therapeutics domain?
  • How is the current and future market opportunity likely to be distributed across key market segments?

For more information about this report visit

Laura Wood, Senior Press Manager

For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Editor Details

  • Company:
    • Businesswire
Last Updated: 08-Jul-2021